INFECTIOUS DISEASE ANTIMICROBIAL REVIEW. Michelle Aguirre Janel Liane Cala PGY1 Pharmacy Practice Residents Medical Center Hospital
|
|
- Shannon Garrett
- 5 years ago
- Views:
Transcription
1 INFECTIOUS DISEASE ANTIMICROBIAL REVIEW Michelle Aguirre Janel Liane Cala PGY1 Pharmacy Practice Residents Medical Center Hospital
2 Objectives Review basic microbiology of organisms Implement MCH Antibiogram utilization Define minimum inhibitory concentration (MIC) Discuss resistant drug organisms and treatment Identify risk factors for common multi-drug resistant pathogens
3 INTRODUCTION
4 Bacterial Morphology
5 Gram Staining organisms/gram-staining.html
6
7 ANTIBIOGRAM, MIC INTERPRETATION
8 MCH Antibiogram Printed each year based on previous year s laboratory data for critical care and medical floors Provided by pharmacy department and the antimicrobial stewardship program Should be reviewed and used to determine proper empiric therapy based on most common organisms seen in different types of infections
9 MIC Interpretation MIC: minimum inhibitory concentration Lowest concentration of an antibiotic that inhibits the growth of a given strain of bacteria Susceptibility Interpretation S (sensitive): organism is inhibited by the serum concentration of the drug that is achieved using recommended dosage I (intermediate): isolates with MICs that approach usually attainable blood and tissue levels and for which response rates may be lower than for susceptible strains R (resistant): resistant to the usually achievable serum drug levels
10
11
12 Case Question VE is a 44-year-old man who was admitted for an abscess. He was started on empiric therapy with pipercillin/tazobactam and vancomycin. Which de-escalation is appropriate based on the following susceptibilities?
13 PATHOGEN DIRECTED RX
14 Is it MSSA or MRSA? Pop Quiz
15 Methicillin Sensitive Staph Aureus (MSSA) Coagulase (+) Catalase (+) Oxacillin sensitive SSTI, PNA, Meningitis, Endocarditis, Osteomyelitis 1 st Line: Penicillinase-resistant Penicillin (Nafcillin, Oxacillin) 1 st Generation Cephalosporins (Cefadroxil, Cefazolin, Cephalexin) Alternatives: Clindamycin, Vancomycin, Tetracycline, Sulfamethoxazole-trimethoprim
16 Methicillin Resistant Staph Aureus (MRSA) Coagulase (+) Catalase (+) Oxacillin resistant SSTI, PNA, Meningitis, Endocarditis, Osteomyelitis 1 st line: Vancomycin (MIC 2 switch agent) Alternatives Daptomycin (not for PNA) Linezolid (for SSTI, PNA) Tigecycline (not for bacteremia) Ceftaroline
17 Methicillin Resistant Staph Aureus (MRSA) Table 1. MRSA Treatment Options Oral Treatment TMP-SMX* Clindamycin* Doxycycline, minocycline* Linezolid IV Treatment Vancomycin Linezolid Daptomycin Ceftaroline Tigecyclineᵃ Quinupristin-dalfopristinᵃ Dalbavancin, oritavancin *for Community Acquired MRSA (CA-MRSA) ᵃSalvage therapy
18 Vancomycin, Daptomycin, and Linezolid All active against gram-positive cocci, including MRSA Table 2. Gram-Positive Drug Class Overview Agent Adverse reactions Pearls Vancomycin Daptomycin Linezolid Infusion reactions, renal toxicity (not contraindicated in AKI), ototoxicity (rare) CPK elevation (obtain baseline and monitor weekly) Bone marrow suppression, peripheral neuropathy, optic neuritis, lactic acidosis MIC 2 associated with treatment failure Do not use in MSSA infections (unless penicillin allergy) Inactivated by pulmonary surfactant do not use for pneumonia Long-term therapy increases risk of AE s Not ideal in UTIs (~30% excreted in urine)
19 Case Question A 33-year-old obese man with a history of recurrent skin abscesses due to MRSA presents to the emergency department with a productive cough, pleuritic chest pain, and dyspnea. One week ago he had influenza. Chest radiography shows multilobar infiltrates and early cavitation. A sputum Gram stain shows numerous gram-positive cocci in clusters. The sputum culture grows S. aureus, which is resistant to oxacillin, has MIC of 6 to vancomycin, and greater than 4 to clindamycin and which are susceptible to daptomycin, linezolid, and quinupristin/dalfopristin.
20 Case Question (continued) Which one of the following antimicrobial regimens would be the best treatment for this patient s infection? a) Daptomycin 6 mg/kg intravenously once daily b) Linezolid 600 mg intravenously twice daily c) Vancomycin 1 g intravenously twice daily d) Ceftriaxone (1 g/d intravenously) plus azithromycin (500 mg/d intravenously) e) Vancomycin (15-20 mg/kg intravenously twice daily) to achieve a trough concentration of 10 to 15 µg/ml plus clindamycin (600 mg intravenously every 8 hours)
21 Enterococcus Gram-positive bacteria in short chains (may appear as streptococcus in pairs/chains in gram-stain report) Present in normal colonic flora, oropharyngeal and vaginal secretions Usually a nosocomial, opportunistic pathogen E. faecalis E. faecium More common Highly virulent Less resistance Less common Less virulence More resistance VRE Vancomycin is the drug of choice for empiric coverage Ampicillin is the drug of choice for enterococcus if susceptible
22 Vancomycin-Resistant Enterococcus Table 4. Usual treatment options based on species VRE (E. Faecalis) Pen G or ampicillin Linezolid Daptomycin Tigecycline Fluoroquinolones Cystitis only: nitrofurantoin, fosfomycin, doxycycline VRE (E. Faecium) Daptomycin Linezolid Quinipristin/dalfopristin* Tigecycline Cyctitis only: fosfomycin, doxycycline *Active against E. faecium but not E. faecalis; salvage therapy
23 Pseudomonas aeruginosa Gram-negative, non-fermenting rod Usually a nosocomial, opportunistic pathogen Usual infections Respiratory: pneumonia GU: UTI/pyelonephritis CV: endocarditis, bacteremia, sepsis Skin/bone: cellulitis, osteomyelitis Risk factors: Immunosuppression, diabetes mellitus, cystic fibrosis, neutropenia, AIDS
24 Treatment Options for Pseudomonas Betalactams Aminoglycosides Fluoroquinolones Polymyxin PCN -Piperacillin/ Tazobactam Cephalosporins Ceftazidime 2g q8 Cefepime 1-2g q8 Ceftazidime/Avibactam 2.5g q8h Ceftolozane/tazobactam 1.5g q8h Amikacin 8 mg/kg THEN 7.5 mg/kg q12h Gentamicin/ Tobramycin 3 mg/kg THEN 2 mg/kg q8h Ciprofloxacin 400 mg q8h Levofloxacin 750 mg q24 Colistin 5mg/kg x1 THEN 2.5mg/kg q12 Polymyxin B 1.25 mg/kg q12 Carbapenems Imipenem/Cilastatin 1g q8h Meropenem 1g q8h Doripenem 500mg q8h OTHER: Fosfomycin 3g PO x 1 Monobactam Aztreonam 2g IV q8h
25 Pop Quiz Patient on piperacillin/tazobactam for 4 days treating HAP and WBC 25, febrile, requiring pressors. Which intravenous antimicrobial agents would be appropriate for a patient with this susceptibility report? A. Piperacillin/tazobactam B. Aztreonam C. Cefepime D. Meropenem
26 Acinetobacter Gram negative, strictly aerobic, nonmotile, coccobacilli Commonly found in: soil, water, catheters, ventilation equipment Usual types of infection: PNA, Septicemia, Burn Wounds Risk factors: Immunosuppression Burns Medical devices (central line, catheter, ventilator, endoscopes, feeding tubes) Previous antibiotic exposure
27 Acinetobacter treatment Imipenem 0.5-1gm IV q6h Meropenem gm IV q 8h Ampicillin/Sulbactam 3g (2:1) q6h Tigecycline 100 mg IV, then 50 mg IV q 12 h Pan-resistant isolates: Colistin + any of the above Variable activity AMG, Cephalosporins, Minocycline, Rifampin, TMP/SMX
28 STENOTROPHOMONAS MALTOPHILIA Aerobic, gram negative bacillus with polar flagella Found mostly in aquatic environment, plants, soil; frequent colonizer of body fluids Nosocomial sources: dh2o, nebulizers, dialysates, contaminated disinfectants Low virulence mostly affects immunocompromised Risk factors: Foreign bodies (catheters) Neutropenia Broad spectrum abx CF
29 STENOTROPHOMONAS MALTOPHILIA Trimethoprim/sulfamethoxazole 15mg/kg/day divided in 2 to 3 doses Ticarcillin/clavulanate Ampicillin/ sulbactam Ceftazidime Ciprofloxacin Levofloxacin Moxifloxacin Doxycycline Colistin (MDR) + COMBI 3.1 g q6h IV 3 g q6h IV 2 g q8h IV 400 mg q8-12h IV mg q24h IV 400mg/day 100 mg q12h IV 2.5 mg/kg q12
30 ESBL (Extended Spectrum Betalactamase)
31 ESBL (Extended Spectrum Betalactamase)
32 Carbapenems- similar outcomes and mortality within class Ceftolozane- Tazobactam** RENAL IAI 1.5g q8h 4-14d + Metronidazole cuti 1.5g q8h x 7days (at least**) Ceftazidime-avibactam** RENAL IAI 2.5g q8h 5-14d + Metronidazole cuti 2.5g q8h x 7days (at least**)- 14d Cefepime 2g q8h variable; not suggested; inferior to carbapenem Piperacillin- Tazobactam- variable; not recommended Fluoroquinolones- Cipro Uncomplicated UTI- Fosfomycin, Nitrofurantoin, Bactrim
33 Pop Quiz JW is a patient who is being seen for an intra-abdominal ESBL infection. In addition, he has a history of poorly controlled seizures for which he takes several antiepileptic drugs. Which of the following carbapenems would you avoid the most in this patient? a) Ertapenem b) Meropenem c) Imipenem/cilastin d) Doripenem
34 Case Question OC is a 42 year-old female with PMH of HTN presenting for complaints of increased urinary frequency and 4/10 suprapubic pain. No fevers and PE is normal. UA shows WBC 17, (+)leukocyte esterases and urine culture shows > 10 5 cfu/ml ESBL E. coli in the urine. PMH: Afib (on Warfarin, Amiodarone) Which outpatient treatment agent could you consider for this patient? a) Meropenem b) Levofloxacin c) Fosfomycin d) Bactrim e) No treatment indicated
35 Carbapenem-Resistant Enterobacteriaceae RISK FACTORS Broad spectrum antibiotic use Trauma Diabetes Indwelling urinary/ venous catheters Mechanical ventilation Immunocompromised malignancy, severe illness, organ transplant
36 Carbapenem-Resistant Enterobacteriaceae includes 70 different genera from Enterobacteriaceae with various mechanisms to become resistant to carbapenems Usual type of infections: VAP, UTI, IAI Exhibit resistance to most beta-lactam antibiotics Optimal treatment is largely unknown
37 Carbapenem-Resistant Enterobacteriaceae Class A (KPC) Klebsiella producing carbapenemase Can be transmitted from Klebsiella to other genera Most common in US Class B (NDM-1) New Delhi Metalloproteases Dependence on Zinc for efficient hydrolysis of betalactams Inhibited by EDTA Very mobile genetic element Class D OXA Hydrolyze oxacillin Heterogenous class 6 subgroups produce carbapenemase not susceptible to betalactam inhibitors Variable response to betalactam inhibitor
38 Carbapenem-Resistant Enterobacteriaceae Polymyxins Colistin -prodrug; slow conversion -renal dose adj Polymyxin B -active drug -no renal dose adj -achieve higher peak concentrations Tigecycline Fosfomycin I: uncomplicated UTI Aminoglycosides I: uncomplicated UTI Most active agent in vitro Possible resistance development with monotherapy ADV: Neurotoxicity*** Nephrotoxicity (>40%) In vitro activity Increased resistance developing Most effective when used in combination Achieve high urinary concentration for prolonged time period Concentration after single dose persist above MIC after 72hrs Good clinical data in UTI but failed therapy with bloodstream infection
39 Carbapenem-Resistant Enterobacteriaceae Combination: Colistin+ Tigecycline + Meropenem extended infusion (2g q8h over 3hrs) Lower mortality rate than monotherapy (27% VS 38%) Advantage: Reduction of initial inappropriate therapy potential synergistic effects suppression of emerging resistance Disadvantage Increased adverse effects Development of Clostridium difficile infection
40 Carbapenem-Resistant Enterobacteriaceae Colistin Polymyxin B Form administered Prodrug Active drug Time until maintenance dose Maintenance dose hours 12 hours Determined by CrCl Lower doses Renal adjustment Yes No Adverse Events Nephrotoxicity (50-60%) Neurotoxicity Pearls Most studied for CRE UTI use: achieves higher concentrations in urine Determined by MIC Higher doses Nephrotoxicity (20-40%) Neurotoxicity May be safer compared to colistin
41 Carbapenem-Resistant Enterobacteriaceae Promising Drug: Ceftazidime- Avibactam possible activity against class A, Class B, class D Betalactamase Avibactam activity against KPCs and OXA, but no activity on NDM1 ADV: N/V/ constipation, anxiety
42 ANTIMICROBIAL STEWARDSHIP Having an antimicrobial stewardship program (with certain components) is required by the Joint Commission MCH antimicrobial stewardship program supported by administration and the members include: Infectious disease physician: Dr. Mocherla Pharmacy leader: Erica Wilson, Lindsay Rumold Pharmacists, laboratory personnel, nurses, physicians, and infection control staff
43 Antimicrobial Stewardship What we do Infectious disease rounds (Tuesdays and Thursdays) with Dr. Mocherla Monitor and report resistance patterns and antibiotic use Projects to improve use of antibiotics Collect data and report stewardship activities to appropriate committees
44 Antimicrobial Stewardship Resources Antimicrobial Stewardship Pocket Guide Completed, printed and distributed, and printed as posters Can also be found on intranet SharePoint site Includes Antibiogram and Antibiotic Use Algorithms CAP, HAP, VAP, aspiration PNA, acute bacterial skin and skin structure infections, UTIs, complicated intra-abdominal infections, complicated intraabdominal infections New pathways to be added: Clostridium difficile infections Meningitis Febrile neutropenia endocarditis
45 Antimicrobial Stewardship Resources Antimicrobial Stewardship SharePoint Site on MCH Intranet Navigate: MCH Home Page > Employee Links (left hand side) > "Antimicrobial Stewardship Follow Link: signin1.0 The following resources will be available on the site: Infectious Disease Guidelines and Resources, MCH Antibiogram, MCH Empiric Antibiotic Use Algorithms, Antibiotic Dosing, Educational Presentations, Infection Control Committee Reports, and Policies & Procedures
46
47 References Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States Atlanta, GA: CDC;2013. Huttner A. Antimicrobial resistance and infection control. Nov ;2(1):31. Arnold R et al. (2011). Emergence of Klebsiella pneumoniae Carbapenemase (KPC)- producing bacteria. South Med J, 104(1) doi: /smj.0b013e3181fd7d5a. Rossolini G et al. (2005). Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa. Clin Microbiol Infect, 11(4): Morril H et al (2014). Treatment options for Carbapenem- Resistant Enterobacteriaceae infections. DOI: /ofid/ofv050 John Hopkins antibiotics guide. (2017). Unbound Medicin. [Mobile application software]. Retrieved from
Mercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016
Mercy Medical Center Des Moines, Iowa Department of Pathology Microbiology Department Antibiotic Susceptibility January December 2016 These statistics are intended solely as a GUIDE to choosing appropriate
More informationNorthwestern Medicine Central DuPage Hospital Antimicrobial Criteria Updated 11/16/16
Northwestern Medicine Central DuPage Hospital Antimicrobial Criteria Updated 11/16/16 These criteria are based on national and local susceptibility data as well as Infectious Disease Society of America
More informationOther Beta - lactam Antibiotics
Other Beta - lactam Antibiotics Assistant Professor Dr. Naza M. Ali Lec 5 8 Nov 2017 Lecture outlines Other beta lactam antibiotics Other inhibitors of cell wall synthesis Other beta-lactam Antibiotics
More information* gender factor (male=1, female=0.85)
Usual Doses of Antimicrobials Typically Not Requiring Renal Adjustment Azithromycin 250 500 mg Q24 *Amphotericin B 1 3-5 mg/kg Q24 Clindamycin 600 900 mg Q8 Liposomal (Ambisome ) Doxycycline 100 mg Q12
More informationPRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE
PRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE Global Alliance for Infection in Surgery World Society of Emergency Surgery (WSES) and not only!! Aims - 1 Rationalize the risk of antibiotics overuse
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More information1. The preferred treatment option for an initial UTI episode in a 22-year-old female patient
1 Chapter 79, Self-Assessment Questions 1. The preferred treatment option for an initial UTI episode in a 22-year-old female patient with normal renal function is: A. Trimethoprim-sulfamethoxazole B. Cefuroxime
More informationAntibiotic Updates: Part II
Antibiotic Updates: Part II Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures
More information21 st Expert Committee on Selection and Use of Essential Medicines Peer Review Report Antibiotics Review
(1) Have all important studies/evidence of which you are aware been included in the application? Yes No Please provide brief comments on any relevant studies that have not been included: (2) For each of
More informationPrinciples of Infectious Disease. Dr. Ezra Levy CSUHS PA Program
Principles of Infectious Disease Dr. Ezra Levy CSUHS PA Program I. Microbiology (1) morphology (e.g., cocci, bacilli) (2) growth characteristics (e.g., aerobic vs anaerobic) (3) other qualities (e.g.,
More informationIntrinsic, implied and default resistance
Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been
More informationUpdates on the Management of Hospital Acquired Infections and Resistant Organisms
Updates on the Management of Hospital Acquired Infections and Resistant Organisms Kaitlin McGinn, PharmD Assistant Clinical Professor, Critical Care Auburn University, Harrison School of Pharmacy November
More informationUpdates on the Management of Hospital Acquired Infections and Resistant Organisms
Updates on the Management of Hospital Acquired Infections and Resistant Organisms Conflict of Interest I, Kaitlin McGinn, have no actual or potential conflict of interest in relation to this program. Kaitlin
More information4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES
CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA BILLIE BARTEL, PHARMD, BCCCP APRIL 7 TH, 2017 DISCLOSURE I have had no financial relationship over the past 12 months with any commercial
More information2015 Antibiotic Susceptibility Report
Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli Haemophilus influenzenza Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens
More informationAntibiotic Abyss. Discussion Points. MRSA Treatment Guidelines
Antibiotic Abyss Fredrick M. Abrahamian, D.O., FACEP, FIDSA Professor of Medicine UCLA School of Medicine Director of Education Department of Emergency Medicine Olive View-UCLA Medical Center Sylmar, California
More informationNew Drugs for Bad Bugs- Statewide Antibiogram
New Drugs for Bad Bugs- Statewide Antibiogram Felicia Matthews, Pharm.D., BCPS Senior Consultant, Pharmacy Specialty BE MedMined Services Disclosures Employee of BD Corporation MedMined Services Agenda
More information2016 Antibiotic Susceptibility Report
Fairview Northland Medical Center and Elk River, Milaca, Princeton and Zimmerman Clinics 2016 Antibiotic Susceptibility Report GRAM-NEGATIVE ORGANISMS 2016 Gram-Negative Non-Urine The number of isolates
More informationAntibiotic Updates: Part I
Antibiotic Updates: Part I Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures
More informationBad Bugs. Pharmacist Learning Objectives. Antimicrobial Resistance. Patient Case. Pharmacy Technician Learning Objectives 4/8/2016
Pharmacist Learning Objectives Antimicrobial Resistance Julie Giddens Pharm D, BCPS Infectious Disease Clinical Pharmacist OSF Saint Francis Medical Center Peoria, IL The speaker has no conflicts to disclose
More informationAntibiotic Stewardship Program (ASP) CHRISTUS SETX
Antibiotic Stewardship Program (ASP) CHRISTUS SETX Program Goals I. Judicious use of antibiotics Decrease use of broad spectrum antibiotics and deescalate use based on clinical symptoms Therapeutic duplication:
More informationAntimicrobial Therapy
Antimicrobial Therapy David H. Spach, MD Professor of Medicine Division of Infectious Diseases University of Washington, Seattle Disclosure: Dr. Spach has no significant financial interest in any of the
More informationMedicinal Chemistry 561P. 2 st hour Examination. May 6, 2013 NAME: KEY. Good Luck!
Medicinal Chemistry 561P 2 st hour Examination May 6, 2013 NAME: KEY Good Luck! 2 MDCH 561P Exam 2 May 6, 2013 Name: KEY Grade: Fill in your scantron with the best choice for the questions below: 1. Which
More informationAntimicrobial Susceptibility Testing: Advanced Course
Antimicrobial Susceptibility Testing: Advanced Course Cascade Reporting Cascade Reporting I. Selecting Antimicrobial Agents for Testing and Reporting Selection of the most appropriate antimicrobials to
More informationConcise Antibiogram Toolkit Background
Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions
More informationStaph Cases. Case #1
Staph Cases Lisa Winston University of California, San Francisco San Francisco General Hospital Case #1 A 60 y.o. man with well controlled HIV and DM presents to clinic with ten days of redness and swelling
More informationAntimicrobial Update. Alison MacDonald Area Antimicrobial Pharmacist NHS Highland April 2018
Antimicrobial Update Alison MacDonald Area Antimicrobial Pharmacist NHS Highland alisonc.macdonald@nhs.net April 2018 Starter Questions Setting the scene... What if antibiotics were no longer effective?
More informationAppropriate Antimicrobial Therapy for Treatment of
Appropriate Antimicrobial Therapy for Treatment of Staphylococcus aureus infections ( MRSA ) By : A. Bojdi MD Assistant Professor Inf. Dis. Dep. Imam Reza Hosp. MUMS Antibiotics Still Miracle Drugs Paul
More informationInfectious Disease 101: Helping the Consultant Pharmacist with Stewardship Principles
Infectious Disease 101: Helping the Consultant Pharmacist with Stewardship Principles Conflicts of Interest None at this time May be discussing off-label indications KALIN M. CLIFFORD, PHARM.D., BCPS,
More informationInfectious Disease: Drug Resistance Pattern in New Mexico
Infectious Disease: Drug Resistance Pattern in New Mexico Are these the world's sexiest accents? Obi C. Okoli, MD.,MPH. Clinic for Infectious Diseases Las Cruces, NM. Are these the world's sexiest accents?
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXIX NUMBER 3 November 2014 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell SM MLS (ASCP), Marti Roe SM MLS (ASCP), Sarah Parker MD, Jason Child PharmD, and Samuel R.
More informationGENERAL NOTES: 2016 site of infection type of organism location of the patient
GENERAL NOTES: This is a summary of the antibiotic sensitivity profile of clinical isolates recovered at AIIMS Bhopal Hospital during the year 2016. However, for organisms in which < 30 isolates were recovered
More informationDiscussion Points. Decisions in Selecting Antibiotics
Antibiotics in Acute Care Fredrick M. Abrahamian, D.O., FACEP, FIDSA Clinical Professor of Medicine UCLA School of Medicine Director of Education Department of Emergency Medicine Olive View-UCLA Medical
More informationUnderstanding the Hospital Antibiogram
Understanding the Hospital Antibiogram Sharon Erdman, PharmD Clinical Professor Purdue University College of Pharmacy Infectious Diseases Clinical Pharmacist Eskenazi Health 5 Understanding the Hospital
More informationAntibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting
Antibiotic Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Any substance of natural, synthetic or semisynthetic origin which at low concentrations kills or inhibits the growth of bacteria
More informationThe β- Lactam Antibiotics. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018
The β- Lactam Antibiotics Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 Penicillins. Cephalosporins. Carbapenems. Monobactams. The β- Lactam Antibiotics 2 3 How
More informationSafe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times
Safe Patient Care Keeping our Residents Safe 2016 Use Standard Precautions for ALL Residents at ALL times #safepatientcare Do bugs need drugs? Dr Deirdre O Brien Consultant Microbiologist Mercy University
More informationInteractive session: adapting to antibiogram. Thong Phe Heng Vengchhun Felix Leclerc Erika Vlieghe
Interactive session: adapting to antibiogram Thong Phe Heng Vengchhun Felix Leclerc Erika Vlieghe Case 1 63 y old woman Dx: urosepsis? After 2 d: intermediate result: Gram-negative bacilli Empiric antibiotic
More informationAntimicrobial Stewardship 101
Antimicrobial Stewardship 101 Betty P. Lee, Pharm.D. Pediatric Infectious Disease/Antimicrobial Stewardship Pharmacist Lucile Packard Children s Hospital Stanford Disclosure I have no actual or potential
More informationStanding Orders for the Treatment of Outpatient Peritonitis
Standing Orders for the Treatment of Outpatient Peritonitis 1. Definition of Peritonitis: a. Cloudy effluent. b. WBC > 100 cells/mm3 with >50% polymorphonuclear (PMN) cells with minimum 2 hour dwell. c.
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST Version 8.0, valid from 018-01-01
More informationAberdeen Hospital. Antibiotic Susceptibility Patterns For Commonly Isolated Organisms For 2015
Aberdeen Hospital Antibiotic Susceptibility Patterns For Commonly Isolated s For 2015 Services Laboratory Microbiology Department Aberdeen Hospital Nova Scotia Health Authority 835 East River Road New
More informationStanding Orders for the Treatment of Outpatient Peritonitis
Standing Orders for the Treatment of Outpatient Peritonitis 1. Definition of Peritonitis: a. Cloudy effluent. b. WBC > 100 cells/mm3 with >50% polymorphonuclear (PMN) cells with minimum 2 hour dwell. c.
More informationSHC Clinical Pathway: HAP/VAP Flowchart
SHC Clinical Pathway: Hospital-Acquired and Ventilator-Associated Pneumonia SHC Clinical Pathway: HAP/VAP Flowchart v.08-29-2017 Diagnosis Hospitalization (HAP) Pneumonia develops 48 hours following: Endotracheal
More informationWhat s next in the antibiotic pipeline?
What s next in the antibiotic pipeline? Jennifer Tieu, Pharm.D., BCPS Clinical Pearls OSHP Spring Meeting Mercy Hospital April 13, 2018 Objective 2 Describe the drug class and mechanism of action of antibiotics
More informationInitial Management of Infections in the Era of Enhanced Antimicrobial Resistance
Initial Management of Infections in the Era of Enhanced Antimicrobial Resistance Robert C Welliver Sr, MD Hobbs-Recknagel Endowed Chair in Pediatrics Chief, Pediatric infectious Diseases Children s Hospital
More informationTable 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities.
Table 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities. Gram-positive cocci: Staphylococcus aureus: *Resistance to penicillin is almost universal. Resistance
More informationAntimicrobial Stewardship Program
Antimicrobial Stewardship Program David R. Woodard, MSc, FSHEA, CIC CDC: Antibiotic Resistance Threats in the United States, 2013 http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ CDC Threat Levels
More informationBreaking the Ring. β-lactamases and the Great Arms Race. Bryce M Kayhart, PharmD, BCPS PGY2 Pharmacotherapy Resident Mayo Clinic - Rochester
Breaking the Ring β-lactamases and the Great Arms Race Bryce M Kayhart, PharmD, BCPS PGY2 Pharmacotherapy Resident Mayo Clinic - Rochester 2015 MFMER slide-1 Disclosures I have no relevant financial relationships
More informationOPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS
HTIDE CONFERENCE 2018 OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS FEDERICO PEA INSTITUTE OF CLINICAL PHARMACOLOGY DEPARTMENT OF MEDICINE, UNIVERSITY OF UDINE, ITALY SANTA
More informationAntimicrobial Susceptibility Patterns
Antimicrobial Susceptibility Patterns KNH SURGERY Department Masika M.M. Department of Medical Microbiology, UoN Medicines & Therapeutics Committee, KNH Outline Methodology Overall KNH data Surgery department
More informationGeneral Approach to Infectious Diseases
General Approach to Infectious Diseases 2 The pharmacotherapy of infectious diseases is unique. To treat most diseases with drugs, we give drugs that have some desired pharmacologic action at some receptor
More information5/4/2018. Multidrug Resistant Organisms (MDROs) Objectives. Outline. Define a multi-drug resistant organism (MDRO)
Multidrug Resistant Organisms (MDROs) Kasturi Shrestha, M.D. 05/11/2018 Objectives Define a multi-drug resistant organism (MDRO) Identify most challenging MDROs in healthcare Identify reasons for health
More informationEUCAST recommended strains for internal quality control
EUCAST recommended strains for internal quality control Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus influenzae ATCC 59 ATCC
More informationPerichondritis: Source: UpToDate Ciprofloxacin 10 mg/kg/dose PO (max 500 mg/dose) BID Inpatient: Ceftazidime 50 mg/kg/dose q8 hours IV
Empiric Antibiotics for Pediatric Infections Seen in ED NOTE: Choice of empiric antibiotic therapy must take into account local pathogen frequency and resistance patterns, individual patient characteristics,
More informationLEARNING OBJECTIVES ANTIMICROBIAL USES AND ABUSES INFECTIOUS DISEASE SCARES
LEARNING OBJECTIVES ANTIMICROBIAL USES AND ABUSES Goodbye to the Antibiotic Era? Glenn D. Bedsole, MD, FACP Infectious Disease Consultant 1. Be able to list 6 examples of resistant bacteria that present
More informationDr. Shaiful Azam Sazzad. MD Student (Thesis Part) Critical Care Medicine Dhaka Medical College
Dr. Shaiful Azam Sazzad MD Student (Thesis Part) Critical Care Medicine Dhaka Medical College INTRODUCTION ICU acquired infection account for substantial morbidity, mortality and expense. Infection and
More informationAntimicrobial Stewardship Programs The Same, but Different. Sara Nausheen, MD Kevin Kern, PharmD
Antimicrobial Stewardship Programs The Same, but Different Sara Nausheen, MD Kevin Kern, PharmD Antimicrobial Stewardship Programs The Same, but Different Objectives: Outline the overall function of an
More informationAntimicrobial Stewardship/Statewide Antibiogram. Felicia Matthews Senior Consultant, Pharmacy Specialty BD MedMined Services
Antimicrobial Stewardship/Statewide Antibiogram Felicia Matthews Senior Consultant, Pharmacy Specialty BD MedMined Services Disclosures Employee of BD Corporation MedMined Services Agenda CMS and JCAHO
More informationa. 379 laboratories provided quantitative results, e.g (DD method) to 35.4% (MIC method) of all participants; see Table 2.
AND QUANTITATIVE PRECISION (SAMPLE UR-01, 2017) Background and Plan of Analysis Sample UR-01 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony
More information2017 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose
2017 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility
More informationAntimicrobial Pharmacodynamics
Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they
More informationSuggestions for appropriate agents to include in routine antimicrobial susceptibility testing
Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing These suggestions are intended to indicate minimum sets of agents to test routinely in a diagnostic laboratory
More informationSimilar to Penicillins: -Chemically. -Mechanism of action. -Toxicity.
Similar to Penicillins: -Chemically. -Mechanism of action. -Toxicity. Cephalosporins are divided into Generations: -First generation have better activity against gram positive organisms. -Later compounds
More informationNew Antibiotics & New Insights into Old Antibiotics
New Antibiotics & New Insights into Old Antibiotics Louisiana Chapter of the American Academy of Pediatrics August 18, 2018 Baton Rouge, Louisiana John Bradley MD Rady Children s Hospital San Diego University
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXXII NUMBER 6 September 2017 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell SM MLS (ASCP), Stacey Hamilton MT SM (ASCP), Samuel Dominguez MD PhD, Sarah Parker MD, and
More informationجداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی
جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی ویرایش دوم بر اساس ed., 2017 CLSI M100 27 th تابستان ۶۹۳۱ تهیه
More information2015 Antibiogram. Red Deer Regional Hospital. Central Zone. Alberta Health Services
2015 Antibiogram Red Deer Regional Hospital Central Zone Alberta Health Services Introduction. This antibiogram is a cumulative report of the antimicrobial susceptibility rates of common microbial pathogens
More informationAntibiotics 201: Gramnegatives
Antibiotics 201: Gramnegatives B. Joseph Guglielmo, Pharm.D. Professor and Dean School of Pharmacy University of California San Francisco Disclosures No potential conflicts of interest. 1 A 77 year old
More informationFighting MDR Pathogens in the ICU
Fighting MDR Pathogens in the ICU Dr. Murat Akova Hacettepe University School of Medicine, Department of Infectious Diseases, Ankara, Turkey 1 50.000 deaths each year in US and Europe due to antimicrobial
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationDisclosures. Principles of Antimicrobial Therapy. Obtaining an Accurate Diagnosis Obtain specimens PRIOR to initiating antimicrobials
Disclosures Principles of Antimicrobial Therapy None Lori A. Cox MSN, ACNP-BC, ACNPC, FCCM Penn State Hershey Medical Center Neuroscience Critical Care Unit Obtaining an Accurate Diagnosis Determine site
More informationCF WELL Pharmacology: Microbiology & Antibiotics
CF WELL Pharmacology: Microbiology & Antibiotics Bradley E. McCrory, PharmD, BCPS Clinical Pharmacy Specialist Pulmonary Medicine Cincinnati Children s Hospital Medical Center January 26, 2017 Disclosure
More informationAntimicrobial Stewardship Strategy: Antibiograms
Antimicrobial Stewardship Strategy: Antibiograms A summary of the cumulative susceptibility of bacterial isolates to formulary antibiotics in a given institution or region. Its main functions are to guide
More informationIntroduction to Pharmacokinetics and Pharmacodynamics
Introduction to Pharmacokinetics and Pharmacodynamics Diane M. Cappelletty, Pharm.D. Assistant Professor of Pharmacy Practice Wayne State University August, 2001 Vocabulary Clearance Renal elimination:
More informationMisericordia Community Hospital (MCH) Antimicrobial Stewardship Report. July December 2013 Second and Third Quarters 2014
H e a l i n g t h e B o d y E n r i c h i n g t h e M i n d N u r t u r i n g t h e S o u l Misericordia Community Hospital (MCH) Antimicrobial Stewardship Report July December 213 Second and Third Quarters
More informationApproach to pediatric Antibiotics
Approach to pediatric Antibiotics Gassem Gohal FAAP FRCPC Assistant professor of Pediatrics objectives To be familiar with common pediatric antibiotics o Classification o Action o Adverse effect To discus
More information2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine
2012 ANTIBIOGRAM Central Zone Former DTHR Sites Department of Pathology and Laboratory Medicine Medically Relevant Pathogens Based on Gram Morphology Gram-negative Bacilli Lactose Fermenters Non-lactose
More informationPIPERACILLIN- TAZOBACTAM INJECTION - SUPPLY PROBLEMS
PIPERACILLIN- TAZOBACTAM INJECTION - SUPPLY PROBLEMS The current supply of piperacillin- tazobactam should be reserved f Microbiology / Infectious Diseases approval and f neutropenic sepsis, severe sepsis
More informationAntimicrobial Chemotherapy
2016 edition by Claudine El-Beyrouty, PharmD, BCPS Department of Pharmacy Thomas Jefferson University Hospital Brian Roslund, PharmD, BCPS, AQ-ID Department of Pharmacy Thomas Jefferson University Hospital
More informationAntibiotics: Selected Topics Steven Park, MD/PhD Director, Antimicrobial Stewardship Program Division of Infectious Diseases UCI Medical Center
Antibiotics: Selected Topics Steven Park, MD/PhD Director, Antimicrobial Stewardship Program Division of Infectious Diseases UCI Medical Center Case 1 60 yo healthy female admitted for fevers and dysuria.
More information2016 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose
2016 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control as recommended by EUCAST Version 5.0, valid from 015-01-09 This document should be cited as "The
More informationRoutine internal quality control as recommended by EUCAST Version 3.1, valid from
Routine internal quality control as recommended by EUCAST Version.1, valid from 01-01-01 Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus
More informationMICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC
MICRONAUT Detection of Resistance Mechanisms Innovation with Integrity BMD MIC Automated and Customized Susceptibility Testing For detection of resistance mechanisms and specific resistances of clinical
More informationRESISTANT PATHOGENS. John E. Mazuski, MD, PhD Professor of Surgery
RESISTANT PATHOGENS John E. Mazuski, MD, PhD Professor of Surgery Disclosures Contracted Research: AstraZeneca, Bayer, Merck. Advisory Boards/Consultant: Allergan (Actavis, Forest Laboratories), AstraZeneca,
More informationAntibiotic stewardship in long term care
Antibiotic stewardship in long term care Shira Doron, MD Associate Professor of Medicine Division of Geographic Medicine and Infectious Diseases Tufts Medical Center Boston, MA Consultant to Massachusetts
More informationNational Clinical Guideline Centre Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults
National Clinical Guideline Centre Antibiotic classifications Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults Clinical guideline 191 Appendix N 3 December 2014
More informationInfectious Disease Issues in the Intensive Care Unit
Infectious Disease Issues in the Intensive Care Unit Catherine Liu, M.D. Assistant Clinical Professor Division of Infectious Diseases University of California, San Francisco Overview Emerging antibiotic
More informationAntimicrobial Susceptibility Testing: The Basics
Antimicrobial Susceptibility Testing: The Basics Susan E. Sharp, Ph.D., DABMM, FAAM Director, Airport Way Regional Laboratory Director, Regional Microbiology and Molecular Infectious Diseases Laboratories
More informationManagement of Hospital-acquired Pneumonia
Management of Hospital-acquired Pneumonia Adel Alothman, MB, FRCPC, FACP Asst. Professor, COM, KSAU-HS Head, Infectious Diseases, Department of Medicine King Abdulaziz Medical City Riyadh Saudi Arabia
More informationNEW ATS/IDSA VAP-HAP GUIDELINES
NEW ATS/IDSA VAP-HAP GUIDELINES MARK L. METERSKY, MD PROFESSOR OF MEDICINE UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE FARMINGTON, CT Mark Metersky, MD, FCCP, FACP is a Professor of Medicine at the University
More information10/13/14. Low: not well absorbed. Good: [blood and tissue] < than if given IV. High: > 90% absorption orally
Low: not well absorbed PO agent not for serious infection nitrofurantoin Good: [blood and tissue] < than if given IV [Therapeutic] in excess of [effective] eg. cephalexin High: > 90% absorption orally
More informationProvincial Drugs & Therapeutics Committee Memorandum Version 2
Provincial Drugs & Therapeutics Committee Memorandum Version 2 16 Garfield Street 16, rue Garfield PO Box 2000, Charlottetown C.P. 2000, Charlottetown Prince Edward Island Île-du-Prince-Édouard Canada
More informationHealth PEI: Provincial Antibiotic Advisory Team Empiric Antibiotic Treatment Guidelines for Sepsis Syndromes in Adults
Health PEI: Provincial Antibiotic Advisory Team Empiric Antibiotic Treatment Guidelines for Sepsis Syndromes in Adults COMMUNITY-ACQUIRED PNEUMONIA HEALTHCARE-ASSOCIATED PNEUMONIA INTRA-ABDOMINAL INFECTION
More informationCARBAPENEM RESISTANT ENTEROBACTERIACEAE (KPC CRE)
CARBAPENEM RESISTANT ENTEROBACTERIACEAE (KPC CRE) Bartsch SM et al. Potential economic burden of carbapenem-resistent Enterobacteriaceae (CRE) in the United States. Clin Microbiol Infect 2017;23(1):48e9-e16.
More informationChildrens Hospital Antibiogram for 2012 (Based on data from 2011)
Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Prepared by: Department of Clinical Microbiology, Health Sciences Centre For further information contact: Andrew Walkty, MD, FRCPC Medical
More informationBACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016)
BACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016) VA Palo Alto Health Care System April 14, 2017 Trisha Nakasone, PharmD, Pharmacy Service Russell Ryono, PharmD, Public Health Surveillance
More informationPharmacology Week 6 ANTIMICROBIAL AGENTS
Pharmacology Week 6 ANTIMICROBIAL AGENTS Mechanisms of antimicrobial action Mechanisms of antimicrobial action Bacteriostatic - Slow or stop bacterial growth, needs an immune system to finish off the microbe
More informationMisericordia Community Hospital (MCH) Antimicrobial Stewardship Report
Misericordia Community Hospital (MCH) Antimicrobial Stewardship Report July December 216 Table of Contents I. Introduction... 3 II. Executive Summary... 5 III. MCH Antimicrobial Utilization Reports...
More information